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I. INTRODUCTION 
Oxysterols produced from oxidation of cholesterol or 
biosynthetic precursors of cholesterol have a variety of 
biological activities. Some of these include cytotoxicity, 
atherogenicity, mutagenicity and carcinogenicity. In 
addition, several oxysterols are potent inhibitors of sterol 
biosynthesis in animal cells. A review of these topics' was 
given by Smith and Johnson recently (1). The biological 
activities of oxysterols have been of particular concern with 
respect to human disease, such as atherosclerosis. Oxysterols 
are toxic to the three major cells of arterial wall, 
endothelial cells (2), smooth muscle cells (3), and 
fibroblasts (4), in vitro. Intravenous or gastric 
administration of oxysterols resulted in aortic lesions 
(5,6). Moreover, oxysterols have been identified in 
oxidized low-density-1ipoprotein (LDL), which is a product 
from cell catalyzed oxidation (7). The presence of 
oxysterols may be related to the cytotoxicity of oxidized LDL. 
The atherogenicity of oxysterols was argued by Higley et al. 
(8) who compared the effect of feeding rabbits pure 
cholesterol and cholesterol oxidation products. They found 
that rabbits fed pure cholesterol exhibited more severe 
arterial lesions than those fed cholesterol-free oxysterols. 
In earlier experiments, we also found that a mixture of 
cholesterol autoxidation products was able to protect rabbits 
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against atherogenesis (9). Rabbits fed a diet containing 1% 
cholesterol developed much more severe aorta fatty streaks 
during an 8-week experimental period than those fed the same 
diet supplemented with the cholesterol oxidation mixture. 
Pre-reaction of the cholesterol autoxidation products with Nal 
completely abolished their effects on preventing atheroma 
formation. Accordingly, the active components in the mixture 
were suggested to be one or more cholesterol hydroperoxides. 
A pair of epimeric cholesterol hydroperoxides were 
isolated from the mixture of cholesterol autoxidation 
products. Their structures were characterized as 20(S)-20,25-
dihydroperoxy-5-cholesten-3B-ol (HP-A) and 20(R)-20,25-
dihydroperoxy-5-cholesten-3B-ol (HP-B) (10). In preliminary 
experiments (11), we found that HP-A and HP-B were very 
effective in inhibition of cholesterol ester synthesis and 
accumulation by mouse peritoneal macrophages that were 
incubated with a cholesterol donor, acetylated low-density-
lipoprotein (Ac-LDL). In cell-free membrane preparation, HPs 
inhibited mouse liver microsomal ACAT activity in a 
concentration dependent way similar to that which was observed 
in the intact cells. Moreover, HPs reduced the degradation 
rate of Ac-LDL by macrophages without causing an accumulation 
of intracellular lipoprotein. These results indicate that HPs 
inhibited macrophage cholesterol ester accumulation through at 
least two different mechanisms, suppression of cholesterol 
esterification and interruption of Ac-LDL metabolism. 
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In the present study, I further investigated the 
inhibitory effect of cholesterol hydroperoxides on ACAT 
activity. The potencies of a variety of oxysterols, synthetic 
or isolated from cholesterol autoxidation products, against 
ACAT were determined. A series of studies were performed to 
characterize the inhibitory mechanism of HPs. I examined the 
possibility that HPs might compete with cholesterol as 
substrate for the enzyme. I also determined the reactivity of 
HPs toward cysteine and methionine residues in protein. The 
chemical nature of ACAT inhibition was investigated with 
specific protein modifying agents and reducing agents. 
Finally, a possible mechanism of ACAT inhibition by HPs was 
proposed. 
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II. LITERATURE REVIEW 
A. Purification and structural properties of ACAT 
Acyl-CoA:cholesterol acyltransferase (ACAT) (EC.2.3.1.26) 
catalyzes the cholesterol esterification by utilizing 
cholesterol and long-chain fatty acyl-CoA as substrates. This 
enzyme is responsible for the major cholesterol ester 
synthesis in a variety of tissues under physiological 
conditions (see rev. 12). Despite its recognize importance, 
the structure and catalytic mechanism of ACAT are not well 
characterized. This is mainly due to the lack of purified 
enzyme. ACAT is a membrane protein that is located in the 
rough endoplasmic reticulum (13,14). Purification of this 
enzyme has been extremely difficult because of its instability 
in the presence of detergents. Moreover, after being 
extracted from the membrane, the enzyme has to be 
reconstituted into liposomes in order to measure its activity. 
A procedure for solubilization, partial purification, and 
reconstitution of pig liver ACAT was reported (15). The 
liver enzyme was extracted with 1.1% deoxycholate in 
combination with 1 N KCl and further purified by ammonium 
acetate fractionation and Sepharose column chromatography. 
The entire procedure produced a 150-fold increase in ACAT 
specific activity with 40% recovery of microsomal enzyme 
activity. Recently, an ACAT-candidate protein with 58 KDa 
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apparent molecular weight was identified from pig liver 
microsomes (16). In this report, the author only briefly 
outlined the scheme of purification, which included 
solubilization with 25 mM CHAPS, Concanavalin-A affinity 
chromatography, free flow isotachophoresis, iso-electric 
focusing, and Mono Q ion-exchange chromatography. The 
purified fractions were resolved by SDS-PAGE and blotted on a 
membrane. Then, ACAT activity was monitored by incubating the 
membrane strips with cholesterol-rich liposomes. Whether the 
58 KDa protein is ACAT or some other esterifying enzyme, such 
as pancreatic cholesterol esterase or cholesterol esterase, 
awaits further investigation. The functional size of ACAT has 
been estimated by a radiation inactivation technique that does 
not require purified enzyme (17). Microsomal ACAT activity, 
measured by using labeled oleyl-CoA as substrate, decreased as 
a simple exponential function of radiation doses, leading to a 
target size of 170-180 KDa. When the size of microsomal acyl-
CoA hydrolase was determined, it was found that this protein, 
approximately 46 kDa, was coupled to a large inhibitor, 
approximately 180 kDa. According to these observations, the 
authors proposed that acyl-CoA hydrolase is the acyl-CoA 
binding component and the inhibitor is the cholesterol-binding 
component of ACAT. 
A systematic survey of the effects of chemical 
modification on ACAT activity was reported by Kinnunen et al 
(18) . It was found that rabbit aortic and liver ACAT was 
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sensitive to sulfhydryl, histidyl, arginyl, and possibly 
tyrosyl modification agents. Base on the sensitivity toward a 
histidyl modification agent, diethyl pyrocarbonate, two 
distinct tissue subtypes of ACAT were identified. The 
apparent of the liver ACAT was 1500 jitM, compared to 40 /xM 
for the aortic ACAT. The existence of two subtypes of ACAT 
was further confirmed in 14 different organs. The authors 
suggested that the heterogeneity of ACAT may contribute to the 
heterogeneous response of ACAT activity in different organs to 
cholesterol feeding. A detailed study of the effect of the 
thiol-modifying agent, p-mercuribenzoate, on ACAT activity 
indicated that there were at least two sulfhydryl groups 
influencing ACAT activity; one was at or near inhibitory 
binding site of coenzyme A, and another was important for 
cholesterol esterification (19). It was noted that 
inhibition of ACAT by modification of histidine and cysteine 
residues suggests the possible similarities of this enzyme to 
another cholesterol esterification enzyme, lecithin 
cholesterol acyltransferase (LCAT), which is responsible for 
plasma cholesteryl ester synthesis. LCAT has been shown to 
contain essential cysteine, histidine, and serine residues 
and a serine residue was possibly involved in the hydrolysis 
of lecithin but not in cholesterol esterification (20). 
Thus, ACAT and LCAT may share some common structural and 
mechanistic features. 
7 
B. Role of ACAT in aortic tissue, liver, and intestine 
The role of ACAT in aortic tissue is of pathological 
interest. It has been considered that vascular ACAT activity 
may be a critical control point for cholesterol ester 
accumulation during atherogenesis (12). Aortic tissues from 
animals with experimental atherosclerosis have very high ACAT 
activity (21,22). Cultured macrophages are widely used as a 
model system to study the process of foam cell formation, a 
prominent feature of atherosclerotic lesions (23). It is 
found that incubation of macrophages with human Ac-LDL or 6-
VLDL isolated from the plasma of cholesterol-fed dogs 
stimulated cellular synthesis and accumulation of cholesteryl 
ester by 20-160 fold (24). The accumulated cholesteryl 
ester in macrophages is stored in the form of cytosolic lipid 
droplets and undergoes a continuous cycle of hydrolysis and 
re-esterification, catalyzed by neutral cholesteryl ester 
hydrolase and ACAT (25). Because the re-esterification of 
cholesterol uses fatty acyl-CoA, which requires ATP for its 
synthesis, the process of hydrolysis and re-esterification is 
energy consuming. Such a futile cycle is speculated to 
contribute to the eventual necrosis of foam cells. The 
cholesterol esterification cycle can be interrupted by the 
presence of high-density lipoprotein (HDL), which releases un-
esterified cholesterol from the cells (26). It has been 
demonstrated that the binding of HDL is reciprocally related 
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to ACAT activity (27,28). Incubation of cholesterol-laden 
macrophages with ACAT inhibitors, such as Sandoz 58.035, 
octimibate, and progesterone, resulted in a time- and dose-
dependent elevation in HDL binding and HDL-mediated 
cholesterol efflux. Thus, the balance of cellular cholesterol 
in macrophages may be maintained by ACAT activity and the HDL-
dependent cholesterol efflux. When ACAT activity is blocked 
the cholesterol level can be regulated by the number of HDL 
binding sites. 
In liver, ACAT activity is also important in maintaining 
the homeostasis of cellular cholesterol. It is found that 
perturbation of cholesterol metabolism by feeding rats 
cholesterol, cholate, or an atherogenic diet increased the 
hepatic cholesterol concentration as well as ACAT activity 
(29). ACAT activity showed a positive correlation with 
changes in the concentration of un-esterified and esterified 
cholesterol. Inducing endogenous cholesterol synthesis by 
intra-gastric administration of mevalonolactone also enhanced 
hepatic ACAT activity. By regulating the ratio of un-
esterified cholesterol to esterified cholesterol in liver, 
ACAT may also be a determinant of secretion of bile acid and 
lipoproteins. It has been reported that injection of the ACAT 
inhibitor, progesterone, into male rats caused an increase in 
biliary cholesterol output (30). The secretion rate of 
biliary cholesterol inversely correlated with the hepatic 
microsomal cholesteryl ester concentration and ACAT activity. 
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This result indicates that cholesterol esterification in liver 
and cholesterol secretion in the bile are coordinately 
regulated. 
HMG-CoA reductase is a key enzyme in cholesterol synthesis 
(31), and it is also a microsomal enzyme. Generally, 
increasing microsomal cholesterol concentration would cause a 
reduction of HMG-CoA reductase activity and a stimulation of 
ACAT activity (32). But, these two enzyme activities are 
not always reciprocally related. For example, feeding rats 
cholestyramine, a bile acid seguestrant, decreased cholesterol 
and bile acid absorption, resulting in an increase in hepatic 
HMG-CoA reductase activity without affecting ACAT activity 
(21). And, experimental hypercholesterolemia induced by 
feeding hamster saturated fatty acid greatly suppressed 
hepatic ACAT activity and cholesterol esterification but did 
not have any effect on HMG-CoA reductase. In contrast, 
cholesterol feeding stimulated cholesterol esterification and 
inhibited the synthesis (33). 
Intestinal ACAT activity is closely related to cholesterol 
absorption. In rat, rabbit, and human intestine, the highest 
ACAT activity is located in the jejunum and proximal ileum 
(34,35) where cholesterol and fat-soluble vitamins are 
mainly absorbed (36). Compound CL 277082 specifically 
inhibited ACAT in microsomes prepared from liver, adrenal, and 
intestinal mucosal cells and had no effect on incorporation of 
fatty acids into triacylglycerol and phospholipid. Feeding 
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rats cholesterol and this compound resulted in a profound 
reduction of plasma and hepatic cholesterol concentrations 
compared with the cholesterol-fed rats. When [^^*0]-
cholesterol was given to trace the fate of cholesterol, it was 
found that animals fed the ACAT inhibitor increased the 
excretion of neutral [^^C]-sterol in the feces (37). The 
regulation of cholesterol uptake and secretion by ACAT was 
demonstrated in the human intestinal cell line, CaCo-2. When 
cells were incubated with PD 128043, a competitive inhibitor 
of ACAT, the incorporation of oleate into cholesterol ester 
was blocked, as was the secretion of newly synthesized 
cholesteryl ester. In a chronic treatment, the inhibitor also 
suppressed the uptake of exogenous cholesterol, which was in 
the form of bile salt micelles (38). 
C. Regulation of ACAT activity 
1. Substrate availability 
The fact that microsomal ACAT activities from a variety of 
tissues can be stimulated by exogenous cholesterol indicates 
that under normal physiological conditions, the cholesterol 
substrate pool for ACAT is not saturated. Thus, ACAT activity 
is limited by the amount of cholesterol available in the 
substrate pool. Because 90% of free cholesterol in cells is 
located in the plasma membrane and, possibly, associated with 
sphingomyelin (39), intracellular cholesterol transport is 
I 
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important in determining the ACAT activity. Treating cultured 
fibroblasts with sphingomyelinase caused a rapid release of 
plasma cholesterol into the intracellular pool. The influx of 
cholesterol resulted in a 15-fold increase in the rate of 
cholesterol esterification (40). In cell-free membrane 
preparations> cholesterol transfer between heterogeneous 
microsomal vesicles (endoplasmic reticulum and plasma 
membrane) also affects ACAT activity. For example, ACAT 
activity increased in a time- and temperature-dependent way, 
even when microsomes were preincubated in the absence of 
exogenous cholesterol (41). The addition of exogenous 
cholesterol in the form of phospholipid liposomes or mixed 
micelles with detergents effectively stimulated microsomal 
ACAT activity (41,42,43). The exogenous cholesterol 
quickly equilibrates with endogenous cholesterol. In one 
example, about 40-50% of newly synthesized cholesteryl ester 
was found to be derived from exogenous substrate (42). 
Some cytosolic factors may facilitate the intervesicular 
cholesterol transport. Inclusion of cytosol in the incubation 
of microsomes with cholesterol-rich liposomes accelerates the 
cholesterol transfer and enhances the ACAT activity (44,45). 
One candidate for such a cytosolic protein is purified from 
rat liver and named sterol carrier protein 2 (SCPg). In vitro 
study demonstrates that SCPg caused a striking increase in 
microsomal ACAT activity as measured by using exogenous added 
[ 14c]-cholesterol or [^'^C] -oleoy 1-CoA (35) . Whether this 
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protein plays a physiological role in intracellular 
cholesterol transfer is unclear. 
2. Covalent modification 
ACAT is possibly regulated by phosphorylation/ 
dephosphorylation as are two other important enzymes in 
cholesterol metabolism, 3-hydroxyl-3-methyl-glutaryl-CoA 
reductase (46) and 7a-hydroxylase (47). Suckling et al 
(48,49) reported that incubation of microsomes prepared 
from rat liver or intestinal epithelial cells with the 
100,OOOxg supernatant in the presence of ATP/Mg++ and NaF 
resulted in an increase in ACAT activity. The activation was 
dependent on the preincubation time and ATP concentration. 
When cholesterol-rich liposomes were included in the pre­
incubation mixture, ACAT activity was further increased. 
Because the activation by ATP-dependent mechanism and by the 
addition of exogenous cholesterol were additive, the authors 
suggested that ACAT may be regulated by both substrate supply 
and (de-)phosphorylation. In another experiment reported by 
Mitropoulos and Venkatesan (41), microsomes were incubated 
with liposomes containing [%]-cholesterol in the presence or 
absence of cytosol. In either case, ACAT activity increased 
with an increase in preincubation time and temperature. The 
presence of cytosol significantly enhanced the rate of 
cholesterol transfer from liposomes to microsomes. The 
elevated cholesterol transfer was abolished if NaF was 
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Included in the preincubation mixture. Thus, the 
Intervesicular cholesterol transfer may be modulated by 
phosphorylation/dephosphorylation and contribute to the change 
of ACAT activity. 
3. Possible physiological inhibitors and activators 
The existence of a short-lived ACAT inhibitor has been 
postulated by two different research groups. Studies with 
Chinese hamster ovary cells demonstrated that the addition of 
a protein synthesis inhibitor, cycloheximide, caused an 
increase in cellular ACAT activity measured in cells incubated 
in lipoprotein-depleted medium. The ACAT activation increased 
with time and reached a maximum at 6-8 hr. Incubation of 
cells with lipoprotein-supplemented medium, 25-
hydroxycholesterol, or an excess of mevalonate all increased 
ACAT activity and abolished the stimulatory effect of 
cycloheximide (50,51). The authors suggested that the 
activation by cycloheximide is possibly due to the depletion 
of a short-lived (turn-over rate; 6-8 hr) inhibitor of ACAT. 
An increase in exogenous cholesterol or in endogenous 
cholesterol synthesis might either block the activity or 
accelerate the degradation of this inhibitor. On the other 
hand, Tabas and Boykow (52) observed that incubation with 
LDL did not cause an increase in ACAT activity nor cholesterol 
ester accumulation in peritoneal macrophages, despite both 
substantial uptake and degradation of LDL in these cells. 
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When peritoneal macrophages were treated with protein 
synthesis inhibitors, cycloheximide, puromycin, or actinomycin 
D, the LDL-induced whole cell ACAT activity and cholesterol 
ester accumulation were 10-fold higher than that seen in the 
LDL-incubated cells. The ACAT activation was detected 4 hr 
after the addition of protein synthesis inhibitors and 
disappeared 4 hr after the removal of inhibitors. ACAT assay 
with cell-free membrane preparations from cycloheximide 
treated cells or control cells showed that the activation 
effect on microsomal cholesterol esterification was much less 
than on the intact cells. Thus, the maximal ACAT activation 
by protein synthesis inhibitors appeared to require the intact 
cell. The authors suggested that another possible mechanism 
for the short-lived inhibitor was to affect the delivery of 
cholesterol to ACAT rather to inhibit the enzyme itself. 
25-Hydroxycholesterol has been shown to stimulate 
cholesterol esterification in a variety of intact cells that 
are incubated in media containing exogenous cholesterol (see 
rev. 1). But, in one example, the ACAT activity measured in 
microsomes isolated from 25-OH treated macrophages was no 
different from that from the control cells (53) . Moreover, 
the stimulatory effect of 25-OH on microsomal ACAT was 
decreased if microsomes were preincubated with cholesterol-
rich liposomes. And, the stimulatory effect was inversely 
related to the microsomal cholesterol content (54). The 
molecular mechanism of ACAT activation by 25-OH is not clear. 
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It has been proposed that the oxysterol may either affect 
cholesterol delivery to the enzyme substrate pool or it may 
interact with a regulatory site on the enzyme (54). 
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III. EXPERIMENTAL 
A. Materials and equipment 
Aprotinin, pepstatin, leupeptin, antipain, benzamidine, 
phosphate buffered saline, dioleoyl-L-a-phosphatidylcholine, 
cholestyramine, glutathione, glutathione disulfide, iodoacetic 
acid, 1-fluoro-2,4-dinitrobenzene, p-hydroxy-mercuribenzoate, 
5,5'-dithio-bis-(2-nitrobenzoic acid), phenylarsine oxide, 
2,3-dimercaptopropanol, dithiothreitol, leucine 
enkephalinamide, methionine enkephalinamide, and cyanogen 
bromide were purchased from Sigma Chemical Co. (St. Louis, 
MO). Sodium cholate, sodium deoxycholate, bovine serum 
albumin, and calmodulin were obtained from Calbiochem Co. (San 
Diego, CA). Reagents used for electrophoresis were purchased 
from Bio-Rad Laboratories (Richmond, CA). [^'^C] -Oleoyl-CoA 
and [%]-oleate were purchased from New England Nuclear Corp. 
(Boston, MA) . Silica gel (40-140 mesh) was purchased from J. 
T. Baker Inc. (Phillipsburg, NY). Hexane and isopropanol were 
purchased from Fisher Scientific (Pittsburgh, PA). 
Scintillation fluid, Ecolume, was supplied by ICN Biomedicals 
Inc. (Costa Mesa, CA). Licrosorb PR-18 and 3-amino-propyl 
HPLC columns were supplied by E. Merck (Darmstadt) and Custom 
LC Inc. (Houston, TX), respectively. Cholesterol purchased 
from Nutritional Biochemical Inc. (Cleveland, OH) was 
recrystallized from methanol three times before use. 20(S and 
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R)-20,25-dihydroperoxy-cholest-5-ene-3B-ol (HP-A and HP-B), 
25-hydroperoxycholesterol, 20(S and R)-20-
hydroperoxycholesterol, and 7a-hydroperoxycholesterol were 
prepared as described by Tipton et al. (10). The following 
hydroperoxides were provided by Dr. M. Ranasinghe, Department 
of Chemistry, Iowa State University, Ames, Iowa: 20(S and R)-
20-hydroperoxycholest-5-ene-3B,25-diol (HP-A' and HP-B'), 
cholest-5-ene-36, 20(S and R), 25-triol (Triol-A and Triol-B), 
20(S and R)-20,25-dihydroperoxy-24-nor-cholest-5-ene-3B-ol 
(HP-llA and HP-llB), 20(S and R)-20,26-dihydroperoxy-
homocholest-5-ene-3B-ol (HP-19A and HP-19B), and 1-(1',5'-
dihydroperoxy-1,5-dimethylhexyl)indan (HP-72A and HP-72B). N-
Methyl-mercaptoacetamide was prepared by reaction of 
ethylmercaptoacetate with methylamine as described (55). 
Equipment used included a Tissumizer homogenizer (Tekmar 
Co., Cincinnati, OH), Sorvall RC-5B centrifuge (Du Pont 
Instruments, Newtown, CN), Beckman L8-80 ultracentrifuge 
(Beckman Instruments Inc., Fullerton, CA), Spectra/Pro 10-
well microdialyzer (Spectrum medical industries Inc., Los 
Angeles, CA), Sonicator Bransonic 12 (Branson Cleaning 
equipment Co., Shelton, CN), bench-top centrifuge, Centra-Mat 
(International Equipment Co., Needham Heights, MA), and 
Hoefer mini-gel apparatus (Hoefer Inc., San Francisco, CA). 
For glutathione analysis, a HPLC system consisting of one . 
SP8700 pump (Spectra Physics Co., ), one ISCO detector 
(ISCO Inc., Lincoln, NE), and one HP 3390A integrator (Hewlett 
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Packard Co., Avondale, PA) was used. Another HPLC system 
consisting of Durai Pump 2350, one detector, Chem Research 
data management and system control from ISCO Inc. was used for 
peptide analysis. Scintillation counter, Beta-trac 6895, was 
purchased from Tm Analytic Co. (Elk Grove Village, IL) . 
B. Methods 
1. ACAT Assay 
Preparation of mouse liver microsomes Male Swiss Webster 
mice were injected intraperitoneal with lipopolysaccharide 4 
days before experiments. Mouse livers were perfused with ice 
cold phosphate-buffered saline and homogenized with Tissumizer 
in a buffer containing 50 mM Tris-HCl, l mM EDTA, pH 7.7 
(buffer A), and a mixture of protease inhibitors, including: 
aprotinin, pepstatin, leupeptin, antipain, and benzamidine. 
The concentrations of aprotinin, pepstatin, leupeptin, and 
antipain were 1 pg/ml and that of benzamidine was 17 ng/ral 
(56). The liver homogenate was centrifuged at 10,000xg 
(Sorvall SS 34 rotor, 9.IK rpm), at 4°C for 30 min, and the 
supernatant was then centrifuged at 100,000xg (Beckman 50 Ti 
rotor, 39K rpm), at 4°C for l hr. The pellet was washed with 
buffer A and centrifuged again. The microsomal pellet was 
collected and re-suspended in buffer A containing protease 
inhibitors to a final concentration approximately 20-28 
protein mg/ml. 
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Extraction of microsomal ACAT Routinely, microsomal 
ACAT was extracted with 1.5% deoxycholate (DOC) combined with 
1 N KCl. Microsomes (0.5 ml) were mixed with 50 mg KCl and 74 
lil buffer A prior to the addition of deoxycholate. One 
hundred microliters 10% deoxycholate was added to the 
microsomes dropwise with slow stirring. The mixture was 
stirred for another 30 min at 4°C and then centrifuged at 
160,000xg ( Beckman SW55 rotor at 4IK rpm) for 1 hr at 4°C. 
The supernatant was collected and diluted with an equal volume 
of 1% sodium chdlate. The protein content in the microsomal 
extract was approximately 5-8 mg/ml. The extract was stored 
at 4°C and used within 2 days. ACAT activity in the 
microsomal extract was detected either after 50-fold dilution 
or after dialysis against buffer A. 
Preparation of lipid/detergent mixture Cholesterol and 
dioleoyl-phosphatidylcholine dissolved in chloroform were 
added to a 13x75mm disposable test tube. Solvent was 
vaporized with a stream of nitrogen. A few drops of diethyl 
ether were added to the lipid layer and the solvent was 
evaporated again. The addition and evaporation of diethyl 
ether were repeated three times, so that the solvent was 
completely removed. To every 10 mg PC, one milliliter of 0.2% 
sodium cholate in buffer A was added. The mixture was flushed 
with nitrogen, and the test tube was sealed with a septum. 
The lipid/detergent mixture was then sonicated in a Bransonic 
sonicator to m aximal clarity> usually 20-30 min. 
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Reconstituted liposomes Liposomes were prepared by 
either a dialysis method (method A) (15) or the cholestyramine 
method (method B) (57). Method A: Twenty microliters of 
microsomal extract was diluted with 180 nl lipid/detergent 
mixture and dialyzed against a constant flow (2.5 ml/min) of 
buffer A into a 10-well microdialyzer at 4°C for 3 hr. 
Reconstituted liposomes formed by this procedure were diluted 
1:5 with buffer A before ACAT assay. Method B: Cholestyramine 
was washed twice with buffer A. To each 0.5 ml lipid/ 
detergent mixture, twenty five minigrams cholestyramine was 
added. After vortexing, the mixture was centrifuged in the 
Centra-Mat centrifuge for 10 min at room temperature. The 
supernatant was treated with 25 mg cholestyramine and 
centrifuged again. Finally, the supernatant was centrifuged 
to remove trace amounts of insoluble materials. Nine portions 
of these liposomes were mixed with one portion of microsomal 
extract. The mixture was allowed to stand at room temperature 
at least 30 min before ACAT activity was measured. 
Assay procedure The assay procedure for ACAT described 
by Chang et al (15) was followed with minimal modification. 
An aliquot of 160 /Ltl diluted microsomes or reconstituted 
liposomes containing 15-200 fig protein was used for each 
assay. The enzyme solution was preincubated 10 min at 37°C 
prior to the addition of 40 /il substrate mixture. The 
substrate mixture consisted of 250 juM [^'^C]-oleoyl CoA (25 
dpm/pmole) and 0.5 mg fatty acid free bovine serum albumin 
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dissolved in buffer A. The assay was terminated after 5 min 
by the addition of 2 ml hexane/isopropanol (3/2, v/v). An 
aliquot of cholesterol-[%]-oleate (about 1000 cpm) dissolved 
in absolute ethanol was introduced into each sample to 
estimate the recovery. Cholesteryl ester was isolated from 
the lipid extract by silica gel chromatography as described by 
Chautan (58). The cholesteryl ester eluate was collected in 
a 7-ml polyvinyl ester scintillation vial. After evaporation 
of solvent, cholesteryl ester was redissolved in 0.2 ml 
hexane/diethyl ether (98/2, v/v), followed by the addition of 
5 ml Ecolume counting fluid. The radioactivity of cholesteryl 
ester was measured by a liquid scintillation counter, Beta-
trac 6895, with channel A setting from 000 to 240 and channel 
B from 240 to 999. 
2. Reaction of ACAT with oxysterols and related compounds 
Reactivity of HP analogs Microsomes (100-200 /xg/assay) 
were preincubated with 31 juM oxysterols or other related 
compounds at 37°C for 15 min. Then, the ACAT assay was 
initiated with the addition of [ -oleoyl-CoA. In the 
control experiment, an equal volume of ethanol was added to 
the microsomes during the preincubation instead of the 
ethanolic solution of the compound being tested. 
Effect of 2 5-hvdroxvcholesterol The effect of 25-OH on 
ACAT activity requires a longer incubation time. Therefore, 
a 60 min incubation was adopted in this case. Thus, 25-OH was 
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added to microsomes or reconstituted liposomes and the mixture 
was incubated for 60 min at 37°C before the ACAT activity was 
determined. 
3. Oxidation of model peptides and protein 
Oxidation of glutathione One volume of ethanol or 10 mM 
ethanolic HP-B was mixed with four volumes of 1 mM glutathione 
or glutathione disulfide dissolved in buffer A. The reaction 
was allowed to proceed at 37°C for 8 hr. After 
lyophilization, the reaction products were reacted with 
iodoacetic acid and 1-fluoro-2,4-dinitrobenzene as described 
(59), and the derivatives were analyzed with HPLC (60) 
with a 3-amino-propyl column. 
Oxidation of enkephalinamide Leucine and methionine 
enkephalinamides (Leu-EPA and Met-EPA) were dissolved in 
buffer A to 1 mg/ml (about 1.7 mM). An equal volume of 10 mM 
ethanolic cumene hydroperoxide (cumene-HP) or HP-B was added 
to the peptide solutions, and the mixtures were incubated at 
37°C. At the stated times, aliguots of the reaction mixture 
were withdrawn and analyzed with an ISCO HPLC system. The 
peptides were eluted with a linear gradient solvent program; 
solvent A was water containing 0.1% trifluoroacetic acid 
(TFA), and solvent B was 75% acetonitrile in water containing 
0.1% TFA. Solvent B was increased from 25 to 40% during the 
first 15 min, and at 40% for another 10 min. The flow rate 
was 0.7 ml/min. Under these conditions, Leu-EPA, Met-EPA, 
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and methionine sulfoxide-EPA (Met(0)-EPA) were eluted at 18.4, 
15.3, and 7.8 min, respectively. When the flow rate was 
increased to 0.85 ml/min, Met-EPA, Met(O)-EPA, and methionine 
sulfone-EPA (Met(0)2-EPA) were eluted at 13.0, 6.0, and 7.2 
min, respectively. 
Met-EPA and its oxidized derivatives were collected from 
HPLC. After evaporation of the solvent, the dry peptides were 
analyzed by mass spectroscopy. The peptides were first 
desorbed from a glycerol matrix and then ionized by fast atom 
bombardment. 
Oxidation of calmodulin Fifty microgram samples of 
calmodulin (1 mg/ml in water) were added to microcentrifuge 
tubes containing 0.5 /nl ethanol, 100 mM ethanolic HP-B or 
Triol-B, or 200 mM 7a-HP. The mixtures were incubated at 37°C 
for 1 hr followed by the addition of an equal volume of 
cyanogen bromide (2 or 20 mg/ml in 70% formic acid). The 
cyanogen bromide reaction proceeded in the dark at room 
temperature for 40 hr (61). At the end of the reaction, the 
mixture was diluted 4-fold with water and then lyophilized. 
The lyophilized calmodulin fragments were rehydrated with 
water and analyzed with SDS-PAGE. A Hoefer mini-gel apparatus 
was used to perform the electrophoresis. Mini-polyacrylamide 
slab gels (15%) were prepared according to Laemmli's procedure 
(62). Protein bands were visualized by staining with 
Coomassie blue G. 
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4. Effects, of thiol-blocking reagents and reducing agents on 
hydroperoxide-treated ACAT activities 
Modification of ACAT with thiol-blockina reagents A 
stock solution of 4 mM p-hydroxy-mercuribenzoate (PMB) was 
prepared by dissolving the compound in buffer A. The solution 
was stored in the dark at room temperature. Microsomes (5 
mg/ml) were incubated with varied concentrations of PMB at 
37°C for 10 min, followed by a 10-fold dilution with buffer A 
with or without 1.3 mM dithiothreitol. ACAT activity was 
measured after 10 min incubation. 
Varied amounts of phenylarsine oxide (PAO) dissolved in 
ethanol were added to microsomes, and the reaction was allowed 
to proceed for 30 min at 37°C . The concentration of ethanol 
in the incubation mixture was 1%. The mixture was diluted 8-
fold with buffer A with or without dithiothreitol or 2,3-
dimercaptopropanol. ACAT activity was determined 30 min after 
the dilution. 
In the cases of double treatment, HP-B was added to PAO-
treated microsomes to a final concentration of 100 /iM, and the 
microsomes were incubated for 15 min before dilution. ACAT 
activity was measured 30 min after dilution. In control 
experiments, ethanol was used to replace the ethanolic 
solution of PAO or HP-B. 
Activation of HP-B-treated ACAT with thiol reducing agents 
Sodium borohydride (NaBH^), 2,3-dimercaptopropanol (DMP), and 
dithiothreitol (DTT) were dissolved in buffer A that was 
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flushed with N2. A 50% N-methyl-mercaptoacetamide (MMA) stock 
solution was prepared and neutralized by 1 N NaOH. 
Microsomes (2-4 mg protein/ml) were reacted with 100 /xM HP-B 
at 37°C for 15 min before the addition of reducing agents. 
The HP-B-treated microsomes were either directly diluted with 
buffer A containing reducing agents or reacted with an equal 
volume of reducing agents and then diluted with buffer A. 
Both short term, 15-30 min, and long term, 3 hr, incubations 
of microsomes in the presence of reducing agents were 
performed. Then, the ACAT activity was determined. 
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IV. RESULTS 
A. ACAT assay 
1. Enzyme solubilization 
A two-step extraction of pig liver microsomal ACAT has 
been developed by Doolittle and Chang (15). Accordingly, 
microsomes were extracted with 0.5% deoxycholate combined with 
1 M KCl, and the insoluble portion was re-extracted with 1.1% 
DOC. They then measured the ACAT activities in the 50-fold 
diluted DOC extracts. By this procedure, they were able 
extract 86% of the microsomal ACAT activity into the 1.1% DOC 
soluble fraction, and the enzyme specific activity was 
increased by 11-fold. I attempted to apply this extraction 
method to mouse liver microsomes, but found that mouse ACAT 
was very soluble in 0.5% DOC. As can be seen in Table 1, the 
0.5% DOC extract contained 73% of total microsomal ACAT 
activity. The specific activity of ACAT in the extract was 
1.8-fold of that in the original microsomes. ACAT remaining 
in the pellets from the first extraction was completely 
solubilized with 1.5% DOC. ACAT was stable through the whole 
procedure of the two-step extraction. The sum of enzyme 
activities of So,5% and S^ g% was equal to the total enzyme 
activity in the original microsomes. Because of the 
solubility of ACAT in 0.5% DOC, the routine preparation of 
microsomal extract was done by directly extracting microsomes 
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Table 1. Extraction of ACAT from mouse liver microsomes. 
Microsomal ACAT was extracted with 0.5% DOC in 
the presence of 1 M KCl. The Insoluble portion 
was resuspended in 1 M KCl and re-extracted 
with 1.5% DOC. So.5% and g% represent the 
soluble fractions." These fractions were 
dialyzed before ACAT activities were measured. 
Po.5% Pi.5% are the insoluble fractions. 
Their enzyme activities were measured after 
resuspending the pellets in buffer A. Each 
value is the mean of two determinations. 
Fractions ACAT activity total activity percent of 
pmole/min/mg pmole/min yield 
Microsomes 120 5256 100 
^0.5% 219 3836 73 
Po.5% 153 1420 27 
^1.5% 383 1436 27 
Pi. 5% 44 157 3 
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with 1". 5% DOC in the presence of 1 M KCl. Microsomal extract 
prepared in this way contained ACAT with specific activity 
1.3- to 2.6-fold of that in the original microsomes. Unlike 
Doolittle's procedure, the measurement of ACAT activity shown 
in Table l was performed after dialysis of the detergent-
soluble fraction for 3 hr against buffer A. ACAT was found to 
be much more active if DOC was removed from the microsomal 
extract by dialysis than if it was simply diluted. For 
example, ACAT activity was 316 pmole/min/mg in a dialyzed 
microsomal extract compared to only 58 pmole/min/mg in a 50-
fold diluted extract. 
2. Effect of cholesterol concentration on the inhibition of 
ACAT by HPs 
The fact that HP-A and HP-B inhibited ACAT activity in the 
intact macrophages and liver microsomes in similar dose-
dependent manners suggests that these two compounds are not 
distinguishable by the enzyme. Therefore, HP-A and HP-B were 
used alternatively in the following experiments. The effect 
of cholesterol concentration on ACAT activity was investigated 
in liposomes in which the lipid compositions were defined. In 
one experiment, HP-A (50 or 127 pmole HP-A per 2 mg 
phosphatidylcholine) was added to a lipid/detergent mixture, 
and the reconstituted liposomes were prepared according to 
Method A described in Experimental. The ratio of HP-A to 
total sterols in liposomes was varied from 3 to 18% or 7.5 to 
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45%. The result is shown in Figure 1. Because ACAT is 
distributed in the lipid bilayer, I express the concentration 
of cholesterol as mole fraction with respect to the total 
lipid in liposomes. In the absence of HP-A, ACAT activity 
increased with the increase of cholesterol concentration in a 
sigmoidal way, and reached the maximum at 0.3 mole fraction of 
cholesterol. The lowest cholesterol concentration, 0.015 mole 
fraction, came from the endogenous cholesterol in the 
microsomal extract. ACAT activity in these liposomes was 
referred to the basal level. In the presence of 37 fiW. HP-A, 
ACAT activity did not vary with cholesterol concentration and 
was only 37% higher than the basal level from 0.1 to 0.4 mole 
fraction cholesterol. With 91 /xM HP-A, ACAT activity did not 
respond to the changes of cholesterol concentration and 
remained at the basal level. In another experiment, reconsti­
tuted liposomes were preformed according to the method B by 
which lipid concentrations in the assay solution was 6.4-fold 
more concentrated than that in the previous experiment. As 
shown in Figure 2, reconstituted ACAT activity was dependent 
on the cholesterol present in the liposomes. The maximal 
activity was reached at 0.4 mole fraction and decreased at 0.6 
mole fraction of cholesterol. The addition of 31 /nM HP-B to 
liposomes greatly suppressed the enzyme activity. Even when 
the cholesterol mole fraction was 0.4, giving a very high 
ratio of total sterol to HP-B, 325, cholesterol was not able 
to protect ACAT from inhibition by HP-B. 
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Figure 1. Effect of cholesterol mole fraction on the 
inhibitory effect of HP-A on ACAT activity. 
Lipid/detergent mixtures with/without HP-A were 
used to prepare the reconstituted liposomes. 
Cholesterol concentrations in the assay 
solution were 233,487, 814,and 1250 juM where 
mole fractions were 0.11, 0.21, 0.30, and 0.40. 
Control (•) had no HP-A. Otherwise, liposomes 
contained either 37 (+) or 91 (*) fM HP-A. 
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Figure 2. Effect of HP-B on ACAT activity in preformed 
liposomes. HP-B 25 juM (•) was added to the 
pre-formed reconstituted liposomes (prepared by 
Method-B). In the assay solutions, cholesterol 
concentrations were 1.4, 3.1, 5.2, 8.1, and 18 
mM where its mole fractions were 0.11, 0.20, 
0.40 and 0.60. In control group (A), ethanol 
was added to replace HP-B. 
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B. Reaction of ACAT with oxysterols and related compounds 
1. Effect of oxysterols on ACAT activity 
Numerous cholesterol hydroperoxides, such as 7(a and B) -
HP, 20(R and S)-HP, and 25-HP, have been found in the mixture 
of air oxidized cholesterol (63,64). I compared their 
activities against ACAT. The results are shown in Figure 3. 
When microsomes were challenged with 31 /iM of each hydro­
peroxide for 15 min, only HP-A and HP-B exerted potent 
inhibition of ACAT activity. This concentration of HP-B has 
been shown to cause maximal ACAT inhibition (11). The 
inhibitory power of the hydroperoxides in sequence is; HP-A, 
HP-B » 20(S or R)-HP > 25-HP, 7a-HP. Several analogs of HP-A 
and HP-B have been synthesized by Dr. M. Ranasinghe and their 
structures are shown in Figure 4. One pair of epimers are 
named HP-A* and HP-B' for their structural similarity to HP-A 
and HP-B. Instead of having two hydroperoxyl groups, HP-A' 
and HP-B' contain only one hydroperoxyl group at C-20 and one 
hydroxy group at C-25. As shown in Table 2, the replacement 
of a hydroperoxyl group by a hydroxyl group at C-25 greatly 
diminished the inhibitory effect. HP-A' and HP-B' affected 
ACAT activity to a similar extent as the other monohydro-
peroxides, 20-HP and 25-HP did. Triol-A and Triol-B contain 
no hydroperoxyl group but nevertheless inhibited ACAT 
slightly. In Table 3, the potency of 62 /xM HP-B' or cumene-HP 
was compared with that of 31 /iM HP-B. As shown, ACAT activity 
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Figure 3. Effect of different cholesterol hydroperoxides 
on ACAT activity. Microsomes were incubated 
with the indicated hydroperoxides for 15 min at 
37°C before the ACAT activities were measured. 
Control: microsomes with no treatment; EtOH; 
only ethanol was added. The enzyme activities 
measured in microsomes with different 
treatments are compared to that in the ethanol 
treated-microsomes. 
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Figure 4. structures of the synthetic HPs analogs 
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Table 2. Effect of reduction of hydroperoxy groups of 
HP-A and HP-B on their potencies as inhibitors 
of ACAT. Microsomes were incubated with 31 /xM 
sterol for 15 min at 37°C before the ACAT 
activities were determined. Each value is the 
mean ± s.d. of two determinations. 
Treatment 
ACAT activity 
pmole/min/mg 
percent of 
control 
Control 463 ± 50 100 
HP-B 167 ± 15 36 
HP-A' 422 ± 10 91 
HP-B' 387 ± 22 84 
Control 763 ± 8 100 
HP-B 183 ± 4 24 
Triol-A 581 ± 40 76 
Triol-B 555 ± 2 73 
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Table 3. Comparison of ACAT-inhibitory effects of mono-
and di-hydroperoxides. Microsomes were 
incubated with different hydroperoxides for 15 
min at 37°C prior to the ACAT assay. Each 
value is the mean ± s.d. of two determinations. 
Treatment 
ACAT activity 
pmole/min/mg 
percent of 
control 
Control 415 ± 1 100 
31 MM HP-B 
o
 
+1 CM CO 20 
62 MM HP-B' 351 ± 4 85 
62 fiVL Cumene-HP 265 ± 6 64 
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was less affected by theformer two compounds than by the 
latter one even though the concentration of hydroperoxyl 
groups in these experiments was the same. HP-11(A and B) and 
HP-19 (A and B) are cholesterol dihydroperoxides with side 
chains either one carbon shorter or one carbon longer than the 
HP-A and HP-B. Their activities against ACAT are shown in 
Table 4. Decreasing the distance between the two hydroperoxyl 
groups by deletion of a methylene group decreased the potency 
slightly. Increasing the distance by one methylene decreased 
the potency (HP-19B) or left it almost unchanged (HP-19A). 
The side chains of HP-72A and HP-72B resemble that of HP-A and 
HP-B, and are connected to an indan rather than the tetra­
cyclic structure of cholesterol. The indan hydroperoxides 
were found to be. as good ACAT inhibitors as were HP-A and HP-B 
(Table 4). The corresponding indan diols were inactive. 
2. Effect of 25-OH on ACAT activity 
25-Hydroxycholesterol (25-OH) has been shown to stimulate 
ACAT activity in intact cells as well as in microsomes (see 
Discussion). Here, a time course study of ACAT stimulation by 
25-OH was performed, and the result indicated that ACAT 
stimulation was time dependent. Figure 5 shows that the 
enzyme activity was increased by 18% after 1 hr incubation 
with 50 /xM 25-OH, whereas a ten min incubation has no 
detectable effect. The stimulatory effect was more 
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Table 4. The activities of synthetic hydroperoxides 
against ACAT. Microsomes were incubated with 
hydroperoxide for 15 min at 37°C before the 
ACAT assay was started. The concentration of 
the sterols and indan derivatives was 31 /iM. 
Each value is the mean ± s.d. of two 
determinations. 
Treatment 
ACAT activity 
pmole/min/mg 
percent of 
control 
Control 703 ± 1 100 
HP-B 335 ± 23 48 
HP-llA 457 ± 7 65 
HP-llB 487 ± 19 69 
HP-19A 385 ± 11 55 
HP-19B 592 ± 28 84 
HP-72A 366 ± 23 52 
HP-72B 391 ± 10 56 
Control 763 ± 8 100 
HP-B 183 ± 4 24 
HP-72A 156 ± 12 20 
Dihydroxyl-72 716 ± 17 94 
I 
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Figure 5. Time-dependent activation of ACAT activity by 
25-hydroxycholesterol. Microsomes were 
incubated with (O) or without (•) 31 /xM 25-OH 
at 37°C. At the indicated times, an aliquot of 
the incubation mixture was withdrawn for ACAT 
assay. 
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profound with freshly prepared microsomes than with pre-frozen 
or heat-treated microsomes. As shown in Table 5, the process 
of freezing and thawing did not affect ACAT activity; however, 
it had a great influence on the stimulatory effect of 25-OH. 
While 25-OH increased the enzyme activity by 42% in the 
freshly prepared microsomes, the pre-frozen microsomes only 
responded by 30% of activation. ACAT was labile to the heat 
treatment, which caused a loss of one third of activity in 3 
min at 60°C. In addition, ACAT became less sensitive to 25-OH 
after the heat treatment. 
The effect of 25-OH was further investigated in the 
reconstituted liposomes. The result is shown in Figure 6. 
25-OH at 31 jtiM enhanced ÀCAT activity in liposomes containing 
0.02 to 0.11 mole fraction of cholesterol and slightly 
decreased the enzyme activity in liposomes with 0.6 mole 
fraction of cholesterol. In the presence or absence of 25-OH, 
the enzyme activity showed a sigmoidal response to the 
increase in cholesterol concentration. 
Figure 7 shows the result of challenging the stimulatory 
effect by HP-B. In this experiment, microsomes were 
sequentially incubated with 25-OH then HP-B or vice versa. 
With 31 fiM 25-OH, ACAT activity was increased by 13% after 75 
min incubation. At the same concentration, HP-B inhibited 57% 
of the enzyme activity. Incubation of 25-OH treated 
microsomes with HP-B totally destroyed the stimulatory effect, 
and furthermore, the enzyme activity was decreased to the same 
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Table 5. Effect of 25-hydroxycholesterol on microsomal 
ACAT activity after heating or freezing. 
Microsomes were prepared according to the 
procedure described in Experimental. A portion 
of microsomes was quick-frozen in dry ice-
cooled ethanol, and ACAT activity was 
determined after thawing the microsomes in a 
22°C water bath. Another portion of microsomes 
was incubated at 60°C for 3, min and the 
precipitate was removed by centrifugation. All 
microsomes were incubated with 31 juM of the 
oxysterol for 1 hr before ACAT activity was 
measured. Each value is the mean ± s.d. of two 
determinations. The degree of activation is 
shown in the parenthesis. 
Microsomes ACAT activity 
-25-OH +25-0H 
pmole/ min/ mg 
Fresh 516 ± 17 735 ± 6 (42%) 
Frozen 515 ± 3 671 ± 28 (30%) 
Heated 357 ± 4 438 ± 3 (23%) 
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Figure 6. Effect of cholesterol concentration changes on 
stimulation of ACAT activity by 25-
hydroxycholesterol. The reconstituted 
liposomes with varied concentrations of 
cholesterol were prepared according to method A 
described in Experimental. 25-OH (+) or an 
e(^al volume of ethanol (•) was added to the 
liposomes, and the mixtures were incubated 1 hr 
before ACAT activity was determined. 
43 
HP-B 25-OH I I BtOH 
CONTROL 
HP-B 
HP-B4-25-OH 
25-OH 
25-OH*HP-B 
1 5  30 45 60 7 5  
PREINCUBATION TIME (MIN) 
90 
! 
E 
1 
600 
500 -
400 -
300 
200 -
100 
CONTROL HP-B HP-B«2S-OH 3S-OH 2S-OH«HP-B 
Figure 7. Effect of 25-hydroxycholesterol on HP-B treated 
ACAT activity. Microsomes were reacted with 
25-OH or HP-B or both in the sequences shown in 
the upper panel. The concentrations of 25-OH 
and HP-B in the incubation mixtures were 31 iM. 
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level as in microsomes treated with HP-B alone. Nor was 25-OH 
able to activate ACAT that had reacted with HP-B. 
C. Oxidation of model peptides and protein 
1. Oxidation of glutathione by HP-B 
Glutathione and glutathione disulfide were used as model 
peptides to study the effect of HP-B on cysteine and cystine 
residues. Glutathione alone was partly oxidized, presumably 
by autoxidation, in buffer A after 8 hr incubation. Table 6 
shows that 40% of glutathione was detected as the disulfide 
form after incubation. The presence of 2 mM HP-B accelerated 
the formation of glutathione disulfide, and only 7.8% of 
glutathione was identified as the reduced form at the end of 
incubation. That is, HP-B converted 52% of cysteine residues 
to cystine. Under the same conditions, glutathione disulfide 
was very stable, and there was no detectable change due to the 
presence of HP-B (data not shown). 
2. Oxidation of EPA by hydroperoxides 
Methionine enkephalinamide (Met-EPA) and leucine 
enkephalinamide (Leu-EPA) are penta-peptides with amidated 
carboxyl terminals. The sequence of EPA is Tyr-Gly-Gly-Phe-X 
and the carboxyl terminal residue is either methionine amide 
or leucine amide. The EPA peptides were used to determine the 
effect of hydroperoxides on peptide methionine residues. The 
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Table 6. Oxidation of glutathione with HP-B. One 
portion of ethanol or 10 mM ethanolic HP-B was 
added to 4 portions of 1 mM GSH. The mixture 
was incubated for 8 hr at 37°C, and the 
reaction products were derivatized and analyzed 
by HPLC. The data represent the mean values of 
two determinations. 
Treatment 
GSH only 
GSH + HP-B 
Mole ratio 
GSH/GSSG 
3.05 
0.16 
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reactions of EPAs with cumene-HP were monitored with the aid 
of HPLC. Both EPA peptides were very stable in buffer A at 
37°C for 24 hours. Leu-EPA was also resistant to the 
challenge of cumene-HP (Figure 8). But, when 5.9-fold excess 
of cumene-HP was added to Met-EPA, a new peptide peak eluted 
at 7.8 min was detected by HPLC after 35 min incubation. As 
shown in Figure 9, the production of new peptide accompanied 
by the disappearance of Met-EPA was time dependent. The peak 
at 31 min is cumene-HP, and the one at 24.5 min is presumably 
cumene hydroxide. The new peptide was collected from HPLC and 
characterized with FAB-mass spectroscopy. The spectra of Met-
EPA and Met(0)-EPA are shown in Figure 10. The new peptide 
has a molecular weight of 588 which is higher than that of 
Met-EPA by 16. The mass difference suggests that the new 
peptide contains one more oxygen atom than Met-EPA. Moreover, 
the difference in reactivity of Leu-EPA and Met-EPA indicates 
that cumene-HP reacted specifically at the methionine residue. 
That is, cumene-HP oxidized the methionine to form methionine 
sulfoxide (Met(O)). Under the same conditions, HP-B oxidized 
Met-EPA at a much slower rate. Met (O)-EPA was observed in the 
reaction mixture of Met-EPA plus HP-B after 8 hr, but not 35 
min. The addition of methanol accelerated the oxidation. In 
the presence of 20% methanol. Met(O)-EPA was formed within 1.5 
hours (data not shown). Another oxidized derivative of 
methionine, methionine sulfone (Met(0)g) was obtained from the 
reaction of Met(O)-EPA with an excess of performic acid. 
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Figure 8, HPLC profile of Leu-EPA reacted with cumene-HP. 
Leu-EPA (1.7 mM) was incubated with 10 mM 
cumene-HP. At the indicated times, an aliquot 
of the reaction mixture was withdrawn and 
analyzed by HPLC. The HPLC conditions are 
described in Experimental, and the flow rate of 
mobile phase was 0.7 ml/min. 
Figure 9. HPLC profile of Met-EPA reacted with cumene-HP. 
Met-EPA (1.7 mM) was incubated with 10 mM 
cumene-HP. At the indicated times, an aliquot 
of the reaction mixture was withdrawn and 
analyzed by HPLC. The HPLC conditions are 
described in Experimental, and the flow rate of 
mobile phase was 0.7 ml/min. 
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Figure 10. FAB-Mass spectra of (A). Met-EPA; (B). Met(O)-
EPA; (C). Met(0)2-EPA. 
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Figure 11 shows the HPLC profile of Met(O)-EPA and Met(O)g-
EPA. The retention times of Met (O)-EPA and Met(0)2-EPA were 6 
and 13 min. The structure of Met(O)g-EPA was also confirmed 
by FAB-mass spectroscopy (Figure 10). Neither cumene-HP nor 
HP-B was able to further oxidize methionine sulfoxide to 
Met(0)2 under our experimental conditions. 
Attempts to reduce 1 mM Met (O)-EPA to Met-EPA with 100 mM 
reducing agents, DTT, DMP, NaBH*, and NHgOH, in one hour 
incubations at 37°C were not successful (data not shown). On 
the other hand, an overnight incubation of 13 jug Met(o)-EPA 
with 0.725 M MMA at 37°C completely restored the Met-EPA. The 
reduction of Met(0)-EPA by MMA is shown in Figure 12. 
3. Oxidation of calmodulin by HP-B 
Bovine brain calmodulin contains nine methionine residues 
and no cysteine residue. It was selected as a model protein 
to study the reaction of protein methionine residues with 
cholesterol hydroperoxides. Calmodulin was reacted with three 
different oxysterols, 7a-HP, HP-B, and Triol-B, for 30 min at 
30°C. The reaction products were degraded by cyanogen bromide 
and characterized in 15% SDS gels. The results are presented 
in Figure 13. Calmodulin from commercial source was resolved 
as two bands with apparent molecular weights of 20 and 18.5 
kDa. I suspect that these two bands correspond to calmodulin 
in two different conformations, with different amount of bound 
Ca"*"^. With large excess of CNBr, this protein was degraded 
Figure 11. Reaction of Met(0)-EPA with an excess of 
perfonnic acid. Met-EPA was reacted with an 
excess of H2O2 for 10 min before the perfonnic 
acid was added (zero time). After the 
addition of performic acid, an aliquot was 
withdrawn at the indicated time and analyzed 
by HPLC. The flow rate of mobile phase was 
0.85 ml/min. 
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Figure 12. Reduction of Met(O)-EPA by MMA. HPLC profiles 
show the starting material, Met-EPA, and 
products from overnight reaction. 
Figure 13. SDS-PAGE separation of CNBr-fragments of 
calmodulin. Calmodulin was treated with or 
without different oxysterols before CNBr 
degradation. The concentrations of CNBr used 
in panel A and panel B were 10 mg/ml and 1 
mg/ml, respectively. The degradation products 
were separated in 15 % acrylamide gels and 
stained with Coomassie blue G. The molecular 
weight marker used in these two gels are the 
same. CaM; calmodulin. 
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into three peptide fragments, one major band with apparent 
molecular weight 11.5 kDa and two minor bands of 15.5, and 8.5 
kDa (Figure 13A). The HP-B treated calmodulin has a very 
different degradation pattern; two major fragments with 
apparent molecular weights of 16.5 and 15.5 kDa, one minor 
fragment of 11.5 KDa, and the 8.5 KDa band was almost 
undetectable. In another experiment (Figure 13B), control 
calmodulin was degraded by CNBr into three fragments, and the 
formation of the two small fragment was inhibited if 
calmodulin was preincubated with HP-B. In contrast, 7a-HP and 
Triol-B have no such effect, and the calmodulin degradation 
patterns after treatment with these compounds are very similar 
to that of the unreacted protein. 
D. Effects of thiol-blocking and reducing agents on the 
activity of hydroperoxide-treated ACAT 
1. Modification of ACAT with PMB and PAO 
Microsomal ACAT was sensitive to the sulfhydryl-modifying 
reagent, PMB, which inhibited ACAT by 97% at a concentration 
of 1.0 mM (Table 7). Inhibition was partly reversible by DTT. 
At 1.3 mM, DTT restored 42-45% of the enzyme activity from 
microsomes exposed to 0.5 or 1.0 mM PMB. Microsomal ACAT was 
also sensitive to PAO, a reagent that reacts preferentially 
with vicinal sulfhydryl groups. As shown in Figure 14, ACAT 
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Table 7. Effect of PMB on ACAT activity. After 10 min 
of reaction with the indicated concentrations 
of PMB, microsomes were diluted 11-fold with 
buffer A with/without DTT and incubated for 10 
min before ACAT assay. The final concentration 
of DTT was 1.3 mM. The percentage activity is 
shown in the parenthesis. 
Treatment ACAT activity 
- DTT + DTT 
pmole/ min/ mg 
Control 555 (100) 534 (96) 
0.5 mM PMB 110 (20) 345 (62) 
1.0 mM PMB 18 (3) 264 (48) 
2.0 mM PMB 15 (3) 136 (25) 
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Figure 14. Effect of PAO on ACAT activity. Microsomes 
were incubated with the indicated 
concentrations of PAO for 30 min at 37°C. 
Microsomes were diluted 8-fold with buffer A 
before the ACAT assay. 
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activity gradually decreased when PAO concentrations were 
above 0.1 mM, and the ICgg of PAO was 180 fM. The specificity 
of PAO for reaction with vicinal sulfhydryls was examined by 
using two thiol reducing agents, DTT and DMP. Table 8 shows 
that DMP but not DTT was able to reverse the PAO reaction. At 
a concentration as low as 0.5 mM, DMP restored ACAT activity 
by 30%. But, increasing the concentration of DMP gave no 
further reactivation, and it was not possible to restore full 
activity. 
Microsomes after reaction with PAO were further challenged 
by HP-B and the abilities of DMP to reactivate the doubly 
treated ACAT were determined. The result is shown in Table 9. 
More than 80% of the enzyme activity was inhibited by 0.5 mM 
PAO, and 20 % of the inhibition was reversed by 2 mM DMP. DMP 
also partially restored ACAT activity from HP-B-treated enzyme 
by 15%. Challenging microsomes with PAO, followed by HP-B did 
not decrease the enzyme activity further. DMP reactivated the 
doubly treated microsomal ACAT to the same extent as it did 
with microsomes reacted with PAO or HP-B alone. Thus, the 
inhibitory effects of PAO and HP-B were not additive. And the 
PAO-treated ACAT was protected from reaction of HP-B. 
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Table 8. Activation of PAO-inhibited ACAT activity by 
DMP and DTT. Microsomes (5 mg protein/ml) were 
incubated with 500 /liM PAO for 30 min at 37°C, 
followed by a 16-fold dilution with buffer A 
containing the indicated concentrations of DMP 
or DTT. ACAT activities were determined 30 min 
after the dilution. Each value is the mean ± 
s.d. of two determinations. 
ACAT activity percent of 
pmole/min/mg control 
Control 176 ± 9 100 
o
 
H
 
+
 mM DTT 164 ± 3 96 
O
 
H
 
+
 mM DMP 192 ± 1 109 
PAO 54 ± 1 30 
+ 1.0 mM DTT 62 + 1 35 
+ 0.5 mM DMP 112 ± 2 63 
o
 
H
 
+
 mM DMP 114 ± 1 64 
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Table 9. Partial protection of ACAT from HP-B by PAO. 
HP-B (0.1 mM) was added to intact or PAO-
reacted microsomes. After 15 min, the mixtures 
were diluted 16-fold with buffer A with or 
without 2 mM DMP. ACAT activity was determined 
after 30 min incubation. Each value is the 
mean ± s.d. of two determinations. 
Treatment ACAT activity percent of 
pmole/min/mg control 
Control 309 ± 70 100 
PAO 58 ± 1 19 
HP-B 72 ± 1 23 
PAO + HP-B 54 ± 5 18 
DMP 267 ± 23 87 
HP-B + DMP 115 ± 11 37 
PAO + DMP 125 ± 24 40 
PAO + HP-B + DMP 82 ± 4 36 
I 
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2. Effect of reducing agents on HP-B-inactivated ACAT activity 
The reversibility of HP-B-inactivated ACAT activity was 
studied by using reducing agents including DTT, NaBH*, DMP, 
and MMA. Table 10 shows the result from DTT treatment. In 
the experiment of the upper panel, microsomes were diluted 
with buffer A containing DTT after the reaction of HP-B. The 
final concentration of DTT was 1.3 mM. With a brief 
incubation at 37°C, no appreciable increase in ACAT activity 
was detected. In the lower panel where higher concentrations 
(20-100 mM) and prolonged incubation (3 hr) was employed, 
ACAT activity was not restored by DTT. In fact, high 
concentrations of DTT caused 50% loss of activity in the 
control microsomes. On the other hand, NaBH*, and DMP were 
able to restore a small amount of ACAT activity. In a short-
term incubation, HP-B-reacted ACAT was activated by 10 to 200 
mM NaBH* by 20% (Table 11) . Table 12 shows the effect of 1-8 
mM DMP on HP-B-treated ACAT activity. DMP at a concentration 
of 1 mM or greater slightly restored enzyme activity by 10%. 
But, considerable ACAT activity was lost at high 
concentrations of NaBH* or DMP. 
N-Methyl-mercaptoacetamide was found to reactivate the 
ACAT activity very effectively (Table 13). While 0.1 mM HP-B 
suppressed 90% of the enzyme activity, incubation of the 
reacted microsomes with 10 mM MMA restored the enzyme activity 
to 55% of the control level. Also, an increase of 43% in the 
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Table 10. Effect of DTT on ACAT activity. In the upper 
panel, microsomes were reacted with or without 
0.1 mM HP-B, followed by a 16-fold dilution 
with buffer A containing DTT. And, ACAT 
activity was determined after 30 min 
incubation. In the lower panel, microsomes 
reacted with or without HP-B were mixed with an 
equal volume of buffer A containing varied 
concentrations of DTT. The mixtures were 
incubated at 37°C for another 3 hr, followed by 
a 10-fold dilution before the ACAT assay. 
ACAT activity percent of 
pmole/min/mg control 
Control 
+ 1.3 mM DTT 1203 • 100 
HP-B 112 9 
+ 1.3 mM DTT 171 14 
Control 1430 100 
+ 20 mM DTT 669 47 
+ 50 mM DTT 691 48 
+ 100 mM DTT 881 62 
HP-B 699 49 
+ 20 mM DTT 536 37 
+ 50 mM DTT 589 41 
+ 100 mM DTT 513 39 
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Table 11. Effect of NaBH* on ACAT activity. Microsomes 
reacted with 0.1 mM HP-B were mixed with an 
equal volume of buffer A containing the 
indicated concentrations of NaBH*. The 
mixtures were incubated at 37°C for another 15 
min. The microsomes were diluted 11-fold with 
buffer A for ACAT assay. 
ACAT activity percent of 
pmole/min/mg control 
Control 530 100 
+ 10 mM NaBH, 506 96 
+ 20 mM NaBH* 434 82 
+ 100 mM NaBH* 402 76 
+ 200 mM NaBH* 296 56 
HP-B 112 21 
+ 10 mM NaBH* 211 40 
+ 20 mM NaBH* 210 40 
+ 100 mM NaBH* 194 37 
+ 200 mM NaBH4 182 34 
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Table 12. Effect of DMP on ACAT activity. Microsomes 
reacted with HP-B were diluted with an equal 
volume of buffer A containing the indicated 
concentrations of DMP for 30 min before an 
aliquot of 160 /il was withdrawn for ACAT assay. 
Each.value is the mean ± s.d. of two 
determinations. 
Treatment 
ACAT activity 
pmole/min/mg 
percent of 
control 
Control 1262 ± 20 100 
+ 4 mM DMP 1103 ± 27 87 
HP-B 178 ± 6 14 
+ 1 mM DMP 314 ± 13 25 
+ 2 mM DMP 314 ± 24 25 
+ 4 mM DMP 323 ± 29 26 
+ 8 mM DMP 255 ± 7 26 
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Table 13. Effect of MMA on ACAT activity. Microsomes 
reacted with or without 0.1 mM HP-B were 
incubated with the indicated concentrations of 
MMA for 3 hr at 37°C. Microsomes were diluted 
10-fold with buffer A before ACAT activity was 
measured. 
Treatment 
ACAT activity 
pmole/min/mg 
percent 
control 
Control 1158 100 
+ 10 mM MMA 1130 97 
+ 100 mM MMA 800 69 
HP-B 124 11 
+ 10 mM MMA 644 55 
+ 100 mM MMA 622 54 
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enzyme activity was detected after incubating the HP-B-reacted 
microsomes with 100 mM MMA. However, ACAT was not very stable 
in the presence of high concentrations of MMA. As shown in 
Table 13, ACAT activity in the control microsomes was reduced 
by 30% by 100 mM MMA. This reagent at 1 M abolished virtually 
all the enzyme activity (data not shown). 
Finally, an experiment was performed to compare the 
reactivities of different reducing agents at the same 
concentration and in the same incubation time. Microsomes, 
intact or HP-B reacted, were incubated with 10 mM of reagents 
for 3 hr, and the ACAT activities were determined after proper 
dilution. As shown in Figure 15, NaBH* was the most effective 
reagent in restoring the ACAT activity and was the least 
damaging to the enzyme. N-Methyl-mercaptoacetamide was also 
quite effective. It restored 40% activity from HP-B reacted 
microsomes even though the intact microsomes lost 28% of 
activity. DTT and DMP appeared to be less useful reagents for 
ACAT activation because they are also inhibitors. 
3. Effect of hydroxylamine and sodium chloride on ACAT 
activity 
When HP-B reacted ACAT was incubated with NH2OH, an 
appreciable degree of re-activation was observed. Figure 16 
shows the effect of NH2OH on ACAT activity at varied 
concentrations. HP-B inhibited 80% of ACAT activity, and the 
lost activity was partially recovered by NH2OH. The activity 
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Figure 15. Microsomes were reacted with (hatched bar) or 
without (solid bar) 0.1 mM HP-B for 15 min 
before incubation with 10 mM of the indicated 
reducing agents. ACAT activity was determined 
after 3 hr incubation at 37°C and a 16-fold 
• dilution with buffer A. Each value is the mean 
of two determinations. 
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Figure 16. Effect of hydroxylamine on microsomal ACAT 
activity. NH2OH at the indicated final 
concentrations was added to microsomes pre-
treated with (+) or without (•) 100 /xM HP-B. 
ACAT activity was measured after 30 min 
incubation. Each value is the mean of two 
determinations. 
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of HP-B-inhibited enzyme was almost triples by 2 M NHgOH. Oh 
the other hand, intact ACAT lost approximately 30-45% activity 
in the incubation with NHgOH alone. Because the NH2OH 
solution was prepared by dissolving NH2OH.HCI in water, 
followed by neutralizing with NaOH, it also contained a 
considerable amount of NaCl. Therefore, the effect of salt on 
ACAT activity was investigated. The result is shown in Table 
14. While 3 M NaCl did not have a significant effect on 
intact ACAT, the salt caused a detectable activation of ACAT 
activity after HP-B treatment. 
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Table 14. Effect of NaCl on ACAT activity. Intact or HP-
B reacted microsomes were incubated in buffer A 
containing the indicated concentrations of NaCl 
for 1 hr at room temperature. Microsomes were 
diluted 11-fold with buffer A before ACAT 
activity was determined. Each value is the 
mean ± s.d. of two determinations. 
Treatment 
ACAT activity 
pmole/min/mg 
percent of 
control 
Control 1496 ± 38 100 
+ 3 M NaCl 1560 ± 22 104 
HP-B 443 ± 10 30 
+ 1 M NaCl 494 ± 2 33 
+ 2 M NaCl 579 ± 22 39 
+ 3 M NaCl 658 ± 6 44 
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V. DISCUSSION 
The aim of the present study was to characterize the 
reaction of cholesterol hydroperoxides, especially HP-A and 
HP-B, with mouse liver acyl-CoA;cholesterol acyltransferase. 
Due to the difficulty in purifying this enzyme, I investi­
gated the problem in the microsomal system. The enzyme 
activity is the only detectable index of the extent of 
reaction between ACAT and the tested compounds. And, our 
interpretation of the results is based on the presumption that 
ACAT is responsible for all cholesterol esterification in 
microsomal preparations. In addition, I took the following 
steps to assure that ACAT activity truly reflected the enzyme 
integrity, l. Microsomes were carefully washed with buffer 
and centrifuged again. In this way, the possible 
contamination by soluble proteins, such as cholesteryl ester 
hydrolase, can be reduced. 2. ACAT activity was measured in a 
short time incubation. Microsomes contain acyl-CoA hydrolase, 
which effectively competes with ACAT for fatty acyl-CoA as 
substrate. A rapid assay prevents the complexity of results 
due to the activity of acyl-CoA hydrolase. 3. Bovine serum 
albumin was added to the assay solution. Both fatty acyl-CoA 
and fatty acid anion have detergent-like properties. The 
albumin acts as a reservoir for fatty acyl-CoA and fatty acid 
anion, preventing them from reaching concentrations at which 
their detergent properties become dominant (65). 
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How do HPS inhibit ACAT activity? Despite their 
structural similarity to cholesterol, HPs are unlikely to act 
as substrate analogs, competitively inhibiting the enzyme. I 
have observed that raising cholesterol concentrations in 
reconstituted liposomes did not protect ACAT from inhibition 
by HPS. As shown in Figure 2, even at a very high ratio (325) 
of cholesterol to HPs, the enzyme activity was still 
inhibited. In the experiment of Table 2, HP-B was added to 
preformed liposomes. Thus, ACAT should be able to bind 
cholesterol to the active site before it was exposed to HP-B. 
The fact that the binding of cholesterol did not prevent the 
interaction of HPs with ACAT suggests that HPs may react with 
enzyme at a region different from the active site. 
It is also possible that HPs were esterified by ACAT to 
form the corresponding ester that did not co-elute with 
cholesteryl ester from silica gel columns. If this is true, I 
might have underestimated the ACAT activity and mis­
interpreted the result as an inhibition of enzyme activity. 
But, this situation was unlikely to happen. In a study of the 
sterol substrate specificity of ACAT, Tavani et al (66) 
found that several 24-alkylsterols, including sitosterol, 
stigmasterol, ergosterol, and lanosterol, were poor substrates 
for the enzyme. Among a series of linear side chain analogs 
of cholesterol, cholesterol was the best substrate for ACAT, 
and analogs with either an increase or decrease in length of 
the side chain were not esterified as effectively. The author 
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concluded that the side chain is very important in the binding 
of substrate to the active site of ACAT. Accordingly, sterols 
with oxygenated side chains are unlikely to be esterified at 
an appreciable rate by ACAT. The HPs, with two oxygenated 
position on the side chain, should be even less likely to 
react. 
With the aid of synthetic HPs analogs, I have demonstrated 
the importance of hydroperoxyl groups in ACAT inhibition. The 
result shown in Table 2 reveals that replacement of one or 
both hydroperoxyl groups with hydroxyl groups greatly 
diminishes the potency of HPs analogs. Table 3 shows that the 
dihydroperoxide, HP-B, reacted with ACAT more effectively than 
the mono-hydroperoxides, HP-B* and cumene-HP. HP-B inhibited 
the enzyme to a greater extent than the mono-hydroperoxides 
did, even though the latter substances were two-fold more 
concentrated than the former one. These observations imply 
that two spatially coordinated hydroperoxyl groups are 
required for maximal potency. I further tested this 
hypothesis with several synthetic dihydroperoxides whose 
structures are shown in Figure 4. All the synthetic 
dihydroperoxides are potent inhibitors of ACAT, and their 
potencies are greater than any of the mono-hydroperoxides I 
have tested. In a series of side chain analogs of HPs, the 
maximal ACAT inhibition was obtained when two hydroperoxyl 
groups were five carbons apart. Either insertion or deletion 
of one carbon in the side chain decreased the inhibitory 
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effect. These results imply that two hydroperoxyl groups 
probably interact with ACAT at two distinct positions. When 
the hydroperoxyl groups are 5 carbons apart, they approach 
these reactive sites most effectively. On the other hand, 
replacement of the tetra-cyclic structure of HPs with an indan 
structure did not reduce the inhibitory effect. Thus, while 
two hydroperoxyl groups directly interact with the enzyme, the 
ring structure may play a supportive role to provide 
sufficient hydrophobicity for the compounds to approach the 
enzyme. 
Generally, hydroperoxides have high oxidation-reduction 
potentials and are considered as oxidants. The simplest 
hydroperoxide is hydrogen peroxide, which has been widely used 
for protein oxidation (67). Under suitable conditions, 
hydrogen peroxide reacts with several functional groups of 
proteins, such as thioether, sulfhydryl, disulfide, imidazole, 
and phenol. In acidic solution (pH<3), hydrogen peroxide 
almost exclusively oxidizes methionine (68), while under 
neutral and slightly alkaline conditions, cysteine, 
tryptophan, and other amino acids are also modified 
(69,70). The reactivity of hydrogen peroxide led me to 
investigate whether HPs would react with cysteine and 
methionine residues in proteins. Although HPs also possibly 
react with tryptophan and histidine, I did not investigate 
these two amino acids in the current study for two reasons: 1. 
Oxidation of tryptophan by hydroperoxide is pH dependent, and 
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the reaction is very slow at pH lower than 8 (69). I usually 
reacted the microsomal enzyme with MPs at pH 7.7. At this pH, 
oxidation of tryptophan is less likely to occur. 2. 
Oxidation of histidine with hydrogen peroxide under mild 
conditions, has only been demonstrated with the free amino 
acid. That hydrogen peroxide failed to modify poly-L-His and 
copoly-His-Glu peptides suggested that histidine residues in 
protein are more resistant to oxidation. 
By using glutathione as a model peptide, I demonstrated 
the oxidation of cysteine residues by HPs (Table 6). Our 
results show that at pH 7.7, HPs oxidized sulfhydryl to 
disulfide and the latter functional group was not further 
oxidized. Little and O'Brien (71) have reported that 
glutathione disulfide and sulfonic acid were the major 
reaction products after oxidation of glutathione with hydrogen 
peroxide or linoleic acid hydroperoxide at pH 8.5 for 22 hr. 
If the reactivities of HPs are similar to those of hydrogen 
peroxide or linoleic acid hydroperoxide, HPs may be able to 
oxidize a sulfhydryl to a sulfonic acid under proper 
conditions. But this did not happen in our experiment. The 
success of the oxidizing the cysteine residue of glutathione 
by HPs suggests a possible reaction that may occur when 
microsomal enzymes were incubated with HP. But, oxidation of 
sulfhydryl groups in proteins is not exactly like that in 
small thiols, such as glutathione. Steric effects are 
important factors that need to be considered for oxidizing a 
I 
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protein sulfhydryl. In some proteins, the steric factor may 
severely impede disulfide formation from hindered sulfhydryls. 
Upon oxidizing a hindered sulfhydryl with a strong oxidant, a 
sulfonic acid will be the main product instead of disulfide 
(72). Therefore, I expect that the oxidation of protein 
cysteine residues with MPs may produce disulfides and, 
possibly, sulfonic acids. 
HPS also oxidize methionine. In the study with Met-
enkephalinamide, I detected the oxidation of the methionine 
residue by HPs with HPLC and identified the reaction product 
as methionine sulfoxide with the aid of FAB-mass spectroscopy. 
To detect the oxidation of methionine residues of calmodulin 
by HP, I took a different approach. Cyanogen bromide has been 
widely used for protein fragmentation. This reagent 
specifically reacts with the thioether group of methionine, 
and alkylates it with a cyano group. The reactive sulfonium 
ion formed then cyclizes and results in peptide bond cleavage. 
However, if methionine is oxidized to methionine sulfoxide, 
this reaction cannot proceed. I took advantage of the 
different reactivities of methionine and methionine sulfoxide 
toward cyanogen bromide to detect the methionine oxidation in 
calmodulin by comparing the degradation patterns. Figure 13A 
shows that after a 30 min incubation, HP-B has oxidized 
certain methionine residues and caused a significant change in 
the cyanogen bromide fragmentation. A new peptide fragment 
with apparent molecular weight 16.5 kDa was derived from the 
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HP-B-reacted calmodulin. The size of the new fragment is only 
slightly smaller than the intact calmodulin, molecular weight 
18.5 KDa, by 2 kDa. Thus, the new peptide has most of the 
structure of calmodulin with only approximately 20 amino acids 
cut off. Walsh et al (61) reported that among 9 methionine 
residues of calmodulin, Met-71, -72, -76, and possibly -109 
are exposed on the surface and most susceptible to oxidation. 
The first three methionine residues are located in the central 
helical region of the protein. The new peptide I detected 
retains the central portion of calmodulin. This result 
suggests that HP-B very likely oxidized these four methionine 
residues. In contrast, 7a-HP did not change the protein 
degradation pattern. Thus, this hydroperoxide has no reaction 
with these methionine residues. Interestingly, HPs but not 
7a-HP at lower concentrations than those used in these 
experiments are effective inhibitors of calmodulin activity in 
the cyclic-AMP phosphodiesterase assay (10). Our current 
result indicates that oxidation of methionine residues at the 
central helix of calmodulin contributes to the protein 
inactivation by HPs. 
The result of the oxidation of cysteine and methionine 
residues in the model systems led me to suspect such reactions 
also occurred when ACAT was incubated with HPs. However, it 
is impossible to directly detect these reactions without a 
purified protein. I then tried to re-activate the HP-reacted 
ACAT with several reagents, expecting that the ability to 
I 
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reverse an unknown protein modification by a specific 
procedure would provide useful information in characterizing 
the nature of the modifying reaction. Four mild reducing 
agents, including DTT, DMP, MMA, and NaBH*, were used for this 
purpose. 
Dithiothreitol, known as Cleland's reagent, has been used 
commonly in the reduction of protein disulfide bonds (73). 
A 30-100 fold excess of DTT was able to reduce exposed 
disulfide bonds within 30 min at pH 8.1 (74). The activity 
of DMP is similar to that of DTT. In addition, 
Dimercaptopropanol is known as anti-lewisite for its potency 
in dissociation of dithioarsenite (75). Sodium borohydride 
also reduces disulfide bonds (76), but this reagent is 
expected only to react with exposed disulfides. For example, 
borohydride selectively reduced one of six disulfides of 
trypsinogen even at very high concentration, 100 mM (77). 
Dedman (78) compared the reactivity of DMP and potassium 
borohydride in the reduction of methionine sulfoxide in 
corticotropin. He found that DMP reduced the hormone after 90 
hr incubation but borohydride failed to do so. MMA reduces 
disulfide bonds as well. It has been reported as most 
effective in reduction of methionine sulfoxide and DTT was 
slightly less effective than MMA (55). Under neutral 
conditions, MMA or DTT at 0.7-2.8 M completely reduced 
methionine sulfoxide to methionine in peptides and proteins at 
37°C in 12-24 hr. Generally, the reduction of methionine 
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sulfoxide requires a higher concentration of the reducing 
agent, longer reaction time, and probably a higher temperature 
than does the reduction of disulfide bond. In some cases, the 
choice of a reducing agent for reduction of methionine 
sulfoxide in a particular protein can be critical. For 
example, while mercaptoethanol was effective in reducing a 
methionine sulfoxide in yeast invertase; DTT and cysteine had 
no effect (79). 
All reducing agents, I tested restored ACAT activity to a 
certain extent under proper conditions (Table 10-13 and Figure 
15). After a 3 hr incubation, both NaBH* and MMA restored 
more than 50% of the enzyme activity from HP-B reacted ACAT. 
And, the effect of NaBH* was detectable even in a 15 min 
incubation (Table 11) . DMP at 1 mM slightly activated the HP-
B reacted ACAT in a 30 min incubation (Table 12), but at a 
higher concentration (10 mM) and for longer incubation time, 
it greatly inhibited the enzyme activity (Figure 15). At 1.3 
mM, DTT did not restored ACAT activity in 30 min incubation. 
At 10 mM for 3 hr incubation, DTT restored a detectable amount 
of HP-B treated ACAT activity but it also greatly decreased 
the unreacted enzyme activity (Figure 15). The fact that all 
these four reducing agents were able to partially restore ACAT 
activity indicates that reduction of either disulfide bonds or 
methionine sulfoxides or both are possibly involved. Under 
our experimental conditions, in terms of the concentrations of 
reagents and incubation time, I expected that disulfide 
83 
reduction would occur more readily than the sulfoxide 
reduction. NaBH* was the most effective reducing agent to re­
activate the HP-B-treated enzyme. This reducing agent has 
been shown to react primarily with exposed disulfide bonds and 
not with hindered ones. Thus, if it is indeed a disulfide 
reduction, the disulfide bond should be easily accessible to 
the medium and to the reducing agents. The differences in 
oxidation-reduction potentials of borohydrlde and thiols may 
account for their effectiveness to reduce the disulfide bond. 
On the other hand, because none of the reducing agents could 
completely restore the enzyme activity, it is possible that 
other types of protein modification also occur. Interestingly, 
DTT and DMP but not MMA or NaBH*, strongly inhibited the 
enzyme at 10 mM, and the former two reagents are both 
dithiols. At this moment, I have no good explanation for this 
result. 
A general survey of the effects of protein modification 
reagents on ACAT activity was performed by Klnnuene et al. 
(18). Their results showed that rabbit liver and aortic ACAT 
were sensitive to the reagents that modify hlstldyl, 
sulfhydryl and arginyl residues. The effect of sulfhydryl 
modification with PMB on ACAT activity was further studied. 
The result suggested that at least two sulfhydryl groups 
Influence ACAT activity: one is at or close to the inhibitory 
CoA binding site and the other is necessary for cholesteryl 
ester formation. Our study with mouse liver ACAT shows that 
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this enzyme also sensitive to PMB modification but in slightly 
different ways. In one experiment, microsomes were incubated 
with 1 mM PMB for exactly 1 min, followed by a 10-fold 
dilution with buffer A with or without 1.3 mM DTT. I found 
that ACAT activity was inhibited to 13% of control, and DTT 
restored the activity to 70% of control (data not shown). 
Under similar conditions, the rabbit enzyme was completely 
inhibited by PMB, and the inhibition could be fully reversed 
by DTT. In another experiment, I increased the PMB reaction 
time to 10 min. By doing this, I found that mouse ACAT was 
inhibited by this thiol-blocking agent in a dose dependent way 
(Table 7) similar to what was reported for the rabbit enzyme. 
However, DTT still failed to restore all the enzyme activity. 
I performed the PMB reaction and ACAT assay in Tris buffer 
containing 1 mM EDTA, whereas Kinnuene did the experiment in 
phosphate buffer without EDTA. I suspect that the buffer 
system may have some effects on the PMB reaction. On the 
other hand, prolonged incubation of ACAT in the presence of 
PMB may have caused a certain degree of protein denaturation. 
An hypothesis of how PMB induces protein denaturation has been 
discussed by Torchinsky (80). The author suggested that if 
a sulfhydryl modified by PMB is participating in an 
interaction with other local residues to maintain the proper 
structure of the protein, such modification will disturb the 
interaction and subsequently destabilize the protein 
conformation. Because the change in conformation may not 
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occur instantaneously after the modification, the protein 
denaturation is therefore sluggish and time dependent. Delay 
in reversing the PMB modification may cause a higher degree of 
protein conformational change, which then requires a longer 
time to be re-natured. The differences in PMB reactivity and 
DTT reversibility may also imply that ACAT from different 
sources are not identical. It is known that the reactivity of 
sulfhydryl groups is influenced by other nearby functional 
groups. For example, charged functional groups will either 
promote or hinder the approach of ionized reagents to 
sulfhydryl groups. And, the neighboring residues can alter 
the degree of ionization of sulfhydryl groups. Thus, 
sulfhydryl groups of the mouse and rabbit enzymes may be 
located in different environments that cause the difference in 
their reactivity. 
ACAT activity was sensitive to another sulfhydryl 
modification agent, PAO. This reagent inhibited the enzyme in 
a concentration dependent way, and the IC50 was 180 /iM. PAO 
is highly specific for modifying vicinal sulfhydryl groups 
(81). It has been used to probe enzymes with proximate 
sulfhydryl groups (20,82). The fact that ACAT is inhibited 
by a low concentration (0.1 to 1.0 mM) of PAO suggests the 
presence of a pair of vicinal sulfhydryl groups that are 
important for the enzyme activity. I further tested the 
specificity of the PAO reaction with two dithiol reducing 
agents, DTT and DMP. It has been shown that upon reaction 
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with arsenoxide, DMP forms a five-member dithioarsenite ring 
that is more stable than the seven-member ring produced from 
DTT (83). Therefore, DMP is specifically used to reverse 
the PAO modification. Our result in Table 8 shows that PAO 
inhibition was partially reversed by DMP, but not DTT. This 
result confirms that the modification by PAO was at vicinal 
sulfhydryl groups, and the modification at these groups causes 
ACAT inhibition. 
The experiments showing restoration of ACAT activity by 
reducing agents indicate that HPs probably oxidized ACAT 
sulfhydryl groups. If that is true, modification of 
sulfhydryl groups with a thiol-blocking agent should be able 
to prevent the reaction with HP. To evaluate this hypothesis, 
I incubated microsomes with PAO before the reaction of HP-B, 
and I determined the enzyme activity after reversing the thiol 
modification. It is shown that DMP was able to restore 15% or 
20% of the ACAT activity from the PAO or HP-B reacted enzyme 
(Table 9). If PAO and HP-B reversibly modified ACAT at 
distinct sites, DMP should be able to restore 35% (15% plus 
20%) of the enzyme activity. But, this was not true. Thus, 
HP-B and PAO must have common modifying sites, the vicinal 
sulfhydryl groups. On the other hand, the sequential 
reaction with HP-B did not further decrease the PAO-treated 
ACAT activity. And the degree of reactivation by DMP from 
PAO-reacted or doubly reacted enzyme are almost the same (20% 
vs 18%). These results indicate that PAO has effectively 
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blocked the reaction of HP-B, and reaction at such 'common 
modification site* by either PAO or HP-B greatly decreased 
ACAT activity. 
Summarizing the results in characterization of ACAT 
inhibition by HP, I have the following conclusions: 1. HPs are 
not competitive inhibitors of ACAT, because increasing 
cholesterol concentration did not affect the inhibitory 
effect. 2. HPs oxidize vicinal sulfhydryl groups ACAT to form 
disulfide bond(s), which was reversible by reducing agents 
including NaBH* and MMA. Oxidation of such vicinal sulfhydryl 
groups greatly decreases the enzyme activity. 3. HPs may 
also react with non-cysteine residues, such as methionine or 
others that can not be protected by PAO, and these reactions 
are more resistant to reducing agents. Modification at these 
residues has less effect on ACAT activity. 
The reaction of a pair of vicinal cysteine residues with 
PAO produces a cyclic dithioarsenite, which can be used to 
estimate the distance between two cysteine sulfur atoms. If 
the reaction of PAO does not cause significant protein 
conformational change, the distance of the two sulfur atoms 
before reaction will be similar to that in the cyclic 
dithioarsenite. The distance between two sulfur atoms in the 
arsenite has been calculated as 3.50-3.62 A (84). This 
distance is much longer than a disulfide bond that is about 
2.0 A (85). How can HPs oxidize these sulfhydryl groups to 
form a disulfide bond? HPs may need to induce a protein 
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conformational change in such a way that two sulfhydryl groups 
come into a proximity that permits the disulfide formation. 
HPS may change enzyme conformation by modifying an amino acid 
residue near the sulfhydryl groups. After reacting with a 
near-by residue, HPs are able to effectively oxidize the 
sulfhydryl groups and form a disulfide bond. Summarizing this 
idea, I further propose a two-step modification model of the 
interaction of HPs with ACAT. The model is illustrated in 
Figure 17. When HP-A or HP-B approaches the vicinal 
sulfhydryl groups, it first modifies a near-by residue with 
one of the hydroperoxyl groups. This modification results in 
a protein conformational change. Then, HPs oxidize the two 
sulfhydryl groups to form disulfide bond. In this model, I 
presume that oxidation of a pair of vicinal sulfhydryl groups 
causes ACAT inhibition by a magnitude much greater than 
modification of other residues. This two-step modification 
model can also explain the observation that HP-A and HP-B were 
more potent than the mono-hydroperoxides, HP-A' and HP-B' 
(Table 2 and 3), because the complete reaction requires two 
hydroperoxyl groups. HP-A' or HP-B' may either react with the 
near-by residue, causing a conformational change without 
significantly affecting the enzyme activity or modify one of 
the sulfhydryl groups to sulfonic acid, if possible, and 
change the enzyme activity. 
Figure 17. A proposed scheme of the ACAT inhibition by HP. 
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Although in our model, the vicinal sulfhydryl groups are ' 
very important for ACAT activity, I do not imply that they are 
directly involved in enzyme catalytic function. There are 
several examples of enzymes sensitive to sulfhydryl 
modification but not having cysteine residues involved in the 
catalytic mechanisms. One of these is lecithin cholesterol 
acyltransferase (LCAT), which catalyzes a reaction similar to 
the ACAT reaction. Researchers found that there are two 
cysteine residues (86) (Cys^^ and Cys^®^) near the serine 
residue at position 181, which was proposed to form an 
oxyester with an acyl group from phosphatidylcholine (87). 
Modification of either cysteine residue decreased the enzyme 
activity (86,87,88,89). Accordingly, it has been proposed 
that the two sulfhydryl groups participate in the catalytic 
mechanism by forming an S-acyl intermediate. However, this 
hypothesis was disproven because a mutant LCAT with the two 
cysteines at positions 31 and 184 replaced by glycines was 
found to be fully active (90). By analogy with LCAT, I 
suggest the vicinal sulfhydryl groups of ACAT may not have 
catalytic functions. Modification of these groups will either 
cause a steric effect that interferes with the substrate 
binding, or a conformational change which deactivates the 
enzyme. 
In the study of the effect of cholesterol on ACAT 
inhibition, I noticed that ACAT activity was dependent on 
cholesterol concentration in a special way. Plotting enzyme 
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activity against cholesterol mole fraction in cholesterol/ 
phosphatidylcholine liposomes, I obtained a sigmoidal curve 
(Figure 1). (Due to the lack of data points between 0.01 to 
0.1 mole fraction of cholesterol, the sigmoidal curvature 
could not be seen in Figure 2). Similar kinetic data have 
also been reported with reconstituted ACAT from Chinese 
hamster ovary cells (91,92). However the author did not 
discuss such observations in detail. Generally, the 
sigmoidicity of an activity-concentration plot suggests the 
presence of a cooperative interaction between binding sites of 
the enzyme. There are two types of cooperative interaction, 
positive and negative. Positive cooperative interaction means 
that the binding of one substrate molecule to the enzyme 
results in an increase in the affinity of the enzyme for the 
next substrates. Due to the lack of purified enzyme, it is 
not known whether ACAT has more than one binding site or 
contains more than one subunit. The kinetic results I 
observed imply that ACAT may be an allosteric enzyme which 
contains more than one subunit or binding site. In order to 
further investigate the cooperative interaction of ACAT active 
sites, I re-plotted the enzyme activity vs cholesterol 
concentration in Figure 1 into Hill coordinates (93), log 
[V/(Vmax-v) ] ; log [S], where v is the enzyme activity, Vmax is 
the maximal activity, and [S] is substrate concentration. The 
Hill coefficient, Njj, is the slope of the tangent of the plot 
at the chosen point. % reflects the nature of cooperative 
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interaction. When % is larger than unity it means a positive 
cooperative effect, and vice versa (94). As shown in Figure 
18, the Ng of ACAT is less than unity when [S] is lower than 
0.04 mole fraction, and % increases and becomes larger than 
unity when [S] is equal to or greater than 0.04 mole fraction. 
This result indicates ACAT may proceed via a complicated 
cooperative interaction between binding sites. For example, 
if ACAT contains three binding sites, binding the first 
cholesterol molecule will decrease the affinity of the enzyme 
for the next substrate molecule. But, when the second site is 
occupied, the enzyme will have a much greater affinity for 
cholesterol. 
The idea that ACAT may be an allosteric enzyme leads us to 
ask if there is a physiological effector of this enzyme? 25-
Hydroxycholesterol has been found to be a potent regulator of 
intracellular cholesterol metabolism. This compound decreases 
cholesterol synthesis by inhibiting HMG-CoA reductase activity 
(95,96). On the other hand, it increases cholesteryl ester 
formation in fibroblasts (97), hepatocytes (98), and 
intestinal cells (54). Drevon et al. (99) reported that 25-
OH stimulated ACAT activity in both intact hepatocytes and 
microsomes, and the stimulation did not require protein 
synthesis. In the study with intestinal cells. Field and 
Mathur (54) demonstrated that the stimulation was inversely 
related to microsomal cholesterol content. At cholesterol 
concentrations.below saturation, 25-OH has a stimulatory 
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Figure 18. Hill plot of the effect of cholesterol 
concentration on ACAT activity. The experiment 
is the same as Figure 1. Only the data from 
control group (no HP-A was added) were 
replotted. 
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effect. And, if ACAT is saturated with respect to 
cholesterol, the oxysterol has no effect. The authors 
suggested two mechanisms for the effect of 25-OH; 1. 25-OH may 
interact with the microsomal membrane and increase the 
cholesterol in the ACAT substrate pool. 2. 25-OH may react 
with ACAT at a regulatory site that is shielded by an excess 
of cholesterol. Up to this time, there is no evidence to 
exclude either mechanism. My study with reconstituted 
liposomes has demonstrated the first time such stimulation can 
be reproduced in an artificial lipid environment. As shown in 
Figure 6, the effect of 25-OH was observed only at cholesterol 
concentrations less than saturation. Our observation not only 
indicates that 25-OH is able to regulate ACAT independent of 
its original lipid environment but also suggests that if any 
other factors are required for ACAT stimulation, they are also 
extractable by deoxycholate and are stable enough to be 
reconstituted. In separate experiments, I further 
demonstrated that the effect of 25-OH on microsomal ACAT was 
time dependent (Figure 5). And the effect was diminished by 
heat or a process of freezing and thawing (Table 5). However, 
our efforts to characterize the ACAT stimulation did not 
enable us to disprove either of the two possible mechanisms. 
In liposomes, 25-OH may interact with lipid vesicles in a way 
that causes cholesterol transfer from one liposome to another. 
Time-dependent activation can be explained as the time-
dependent cholesterol transfer. Heat and cold treatments both 
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can cause membrane lipid re-arrangements which subsequently 
may affect the availability of cholesterol to the enzyme. 
Alternatively, I can explain that the time-dependent ACAT 
activation is due to a slow protein conformational change 
induced by an allosteric effector, 25-OH. It has been 
discussed by Kurganov (100) that the magnitude of the 
effect of an effector on enzyme.activity depends on the time 
of contact of the enzyme with the effector. This is because 
the conformational change induced by the effector does not 
proceed instantaneously but at a finite rate. On the other 
hand, the heat or freezing treatment may change protein 
conformations that also affects the affinity of the effector 
binding site. 
From the result shown in Figure 7, I conclude that if 
there is a regulatory site for 25-OH, the binding of oxysterol 
has no effect on ACAT inhibition by HPs. Thus, HPs probably 
attacks ACAT at a site other than an effector binding site. 
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VI. CONCLUSION 
In the present study, I have demonstrated that 20(R and 
S)-20,25-dihydroperoxy-5-cholesten-36-ol (HPs) are the two 
most potent ACAT inhibitory oxysterols isolated from 
cholesterol autoxidation products. The side chain structure 
of HPS are critical for the potency, but a replacement of the 
tetra-cyclic structure with an indan did not affect their 
activities. HPs inhibit ACAT through chemical modification 
rather than competition with cholesterol as enzyme substrates. 
Experiments with reconstituted liposomes showed that 
cholesterol at an extremely high ratio to HPs failed to 
protect ACAT from inhibition. With model peptides and 
protein, including enkephalinamides, glutathione', and 
calmodulin, I have demonstrated that HPs oxidize protein 
sulfhydryl and thioether groups and the reaction products are 
disulfide and methionine sulfoxide. Without the purified 
ACAT, it is not possible for us to directly detect the 
reaction of HPs with the enzyme. However, the fact that 
reducing agents, DTT, DMP, MMA, and NaBH* partially restored 
the HP-B-treated ACAT activity suggests that cysteine and 
methionine oxidation possibly occurred. ACAT was sensitive to 
PME and PAO, indicating that sulfhydryl, specifically, vicinal 
sulfhydryl groups are important for the enzyme activity. The 
reactions of these two thiol-modifying reagents with ACAT were 
partially reversed by DTT and DMP. Dimercaptopropanol 
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restored ACAT activity from PAO and HP-B doubly treated 
microsomes as effectively as from the PAO-treated microsomes. 
Thus, the major effect of HPs on ACAT activity is likely due 
to the reaction with vicinal sulfhydryl groups. Summarizing 
all the observations, I propose a scheme of sequential 
modification to explain the inhibitory effect of HPs on ACAT. 
That is, HPs first oxidize an unknown residue causing a 
protein conformational change without significantly affecting 
the enzyme activity. Then, HPs oxidize a pair of vicinal 
sulfhydryl groups to form a disulfide bond that results in a 
great loss in ACAT activity. 
In addition, two unique features of ACAT activity have 
been observed in the present study. 1. ACAT activity shows a 
sigmoidal response to an increase in cholesterol 
concentration. This result implies that ACAT may have 
multiple cholesterol binding sites that interact with each 
other cooperatively. 2. 25-Hydroxycholesterol was able to 
stimulate ACAT activity even though the enzyme was isolated 
from its original lipid environment and reconstituted in to 
liposomes. 
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